Tuesday, October 4, 2022


Biotechnology News Magazine

THR-149 Phase 2 Clinical Trial New Data Reported

Latest Posts

Sonrava Health to Include the PreTRM® Test in Its Employee Maternity Benefits Package in Collaboration with Cerebrae and Sera Prognostics

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and...

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

THR-149 Phase 2 Clinical Trial: Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in vascular retinal disorders, presented new data from Part A of its two-part Phase 2 Clinical Trial (“KALAHARI”) assessing THR-149 for treatment of diabetic macular edema (DME) at the Angiogenesis, Exudations, and Degeneration 2022 Meeting on February 11-12th.

THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the 40-50% of DME patients showing suboptimal response to anti-VEGF therapy. High-level Month 3 data from Part A of the KALAHARI trial was first presented in October 2021 and demonstrated that in the 8 patients who received the highest dose of THR-149, a mean BCVA gain of 6.1 letters at Month 3, the primary endpoint, was observed.

The new data reviewed today is a post-hoc analysis of an OCT (Optical Coherence Tomography) biomarker assessment, which was performed by the masked central reading center. The masked reading center identified two subjects with abnormalities at baseline, which could impact responsiveness to treatment. Excluding these two subjects resulted in an improvement in mean BCVA of 9.3 letters at Month 3 that was sustained until Month 6, the end of the trial. The six-month data also demonstrated THR-149’s attractive safety profile and its ability to stabilize the Central Subfield Thickness (CST).

“The data presented today continues to highlight THR-149’s compelling safety and efficacy profile in patients with diabetic macular edema,” commented Arshad M. Khanani, M.D., M.A., Director of Clinical Research at Sierra Eye Associates, Reno, Nevada, US. “For patients who are suboptimal responders to standard of care anti-VEGF therapy, the post-hoc analysis of the high-dose cohort in the KALAHARI trial showed encouraging gains in BCVA with over 80% of patients gaining at least 5 letters and 50% of patients gaining at least 10 letters four months after the last THR-149 injection. In addition, CST was stable up to Month 6. These results demonstrate the potential of THR-149 to make a meaningful difference to this patient population, which if left untreated would be expected to experience a further deterioration in their vision.”

Based on Month 3 Part A data, the high dose of THR-149 was selected for Part B of the KALAHARI study to compare vs. aflibercept for the treatment of DME. The learnings from the Part A data presented today have already been incorporated into Part B through an amended study design, which has been approved by the US IRB. The approved protocol amendment optimizes the inclusion and exclusion criteria for Part B and eliminates subjects with potential baseline abnormalities, to further increase the potential for response to treatment. Part B of the trial is currently enrolling with topline data expected mid-2023.

Tom Graney, CFA, Chief Executive Officer of Oxurion, said, “The data Dr. Khanani presented improves our understanding of which patients are most likely to respond to treatment and underscores the potential of THR-149 to address the significant unmet need in patients that experience a suboptimal response to anti-VEGFs and currently lack adequate treatment options. We believe these changes will maximize our ability to achieve a successful trial outcome to the benefit of patients while preserving the positive attributes of the initial trial design and maintaining our timelines.”

Part B of the KALAHARI trial is ongoing, assessing three monthly injections of THR-149, compared to three monthly injections of aflibercept, up to Month 3. As from Month 3, the safety and efficacy of a switched fourth injection (THR-149 to aflibercept or aflibercept to THR-149) will be evaluated in about half of the subjects whereas in the other half of the subjects the durability of three monthly injections (THR-149 or aflibercept) will be assessed through a single sham injection. The trial is planned to randomize approximately 108 subjects in Part B and the primary endpoint remains the mean change in BCVA letter score from baseline, at Month 3.

All dose levels of THR-149 demonstrated a favorable safety profile during Part A of the KALAHARI trial, which was maintained through the end of the trial. All adverse events in the study eye were mild to moderate in intensity and no severe ocular adverse events were reported and no intra-ocular inflammation observed.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine